In sustained remission: After full criteria for cannabis use disorder were previously met, none of the criteria for cannabis use disorder have been met at any time during a period of 12 months or longer (with the exception that Criterion A4, “Craving. or a strong desire or urge to use cannabis," may be present).
Specify it:
In a controlled environment: This additional specifier is used it the individual is in an environment where access to cannabis is restricted.
Code based on current severity: Note for |CD-10-CM codes: If a cannabis intoxication, cannabis withdrawal, or another cannabis-induced mental disorder is also present, do not use the codes below for cannabis use disorder. Instead, the comorbid cannabis use disorder is indicated in the 4th character of the cannabis-induced disorder code (see the coding note for cannabis intoxication. cannabis withdrawal. or a specific cannabis-induced mental disor- der). For example. if there is comorbid cannabis-induced anxiety disorder and cannabis use disorder, only the cannabis-induced anxiety disorder code is given. with the 4th character indicating whether the comorbid cannabis use disorder is mild, moderate, or severe:
F12.180 for mild cannabis use disorder with cannabis-induced anxiety disorder or F12.280 for a moderate or severe cannabis use disorder with cannabis-induced anxiety disorder.
Specify current severity: 305.20 (F12.10) Mild: Presence of 2-3 symptoms.
304.30 (F12.20) Moderate: Presence of 4—5 symptoms.
304.30 (F12.20) Severe: Presence of 6 or more symptoms.
”In a controlled environment" applies as a further specifier of remission if the individual is both in remission and in a controlled environment (i.e., in early remission in a controlled environment or in sustained remission in a controlled environment). Examples of these environments are closely supervised and substance-free jails, therapeutic communities, and locked hospital units.
frequency (e.g., days of use per month or times used per day) and / or dose (e.g., amount used per episode) of cannabis, as assessed by individual self—report, report of knowledge- able others, clinician’s observations, and biological testing.
Cannabis use disorder and the other cannabis-related disorders include problems that are associated with substances derived from the cannabis plant and chemically similar syn- thetic compounds. Over time, this plant material has accumulated many names (e.g., weed, pot, herb, grass, reefer, mary jane, dagga, dope, bhang, skunk, boom, gangster, kit, and ganja). A concentrated extraction of the cannabis plant that is also commonly used is hashish. Cannabis is the generic and perhaps the most appropriate scientific term for the psychoactive substance(s) derived from the plant, and as such it is used in this manual to refer to all forms of cannabis-like substances, including synthetic cannabinoid com- pounds.
Synthetic oral formulations (pill/capsules) of delta-9-tetrahydrocannabinol (delta-9-
THC) are available by prescription for a number of approved medical indications (e.g., for with AIDS). Other synthetic cannabinoid compounds have been manufactured and dis- tributed for nonmedical use in the form of plant material that has been sprayed with a can- nabinoid formulation (e.g., K2, Spice, IWH-018, IWH-073).
The cannabinoids have diverse effects in the brain, prominent among which are actions on C31 and C32 cannabinoid receptors that are found throughout the central nervous sys- tem. Endogenous ligands for these receptors behave essentially like neurotransmitters.